Results 1 to 10 of about 27,744 (249)
The Usage of Concomitant Beta-Blockers with Vasopressors and Inotropes in Cardiogenic Shock [PDF]
Medical Sciences, 2022 Vasopressors and inotropes (Vs/Is) are widely used in the treatment of cardiogenic shock (CS). Despite improvements in hemodynamic variables and end-organ perfusion, these agents have been associated with an increase in mortality, potentially due to the ...
Rachel Ryu +3 more
doaj +3 more sources
Общая реаниматология, 2022 Inotropes and vasopressors are frequently required in critically ill patients and in patients undergoing major surgery. Several molecules are currently available, including catecholamines, phosphodiesterase-3 inhibitors, vasopressin and its analogues ...
A. Belletti +5 more
doaj +4 more sources
National shortage of home intravenous inotrope agents: The “inotrope pandemic” continues
JHLT Open, 2023 Dipan Uppal, MD +7 more
doaj +2 more sources
Role of Arterial Serum Lactate as a Predictor of Undifferentiated Shock on Admission and its Outcome- A Cohort Study [PDF]
Journal of Clinical and Diagnostic Research, 2021 Introduction: Patients with elevated serum lactate levels may be at risk for considerable morbidity and mortality and require a prompt, thoughtful and systematic approach for diagnosis and treatment.
Avadhesh Kumar Sharma +4 more
doaj +1 more source
Usefulness of Myocardial Injury Parameters in Predicting Prolonged Postoperative Use of Inotropes Drugs in Patients Undergoing Heart Valve Surgery. [PDF]
J Clin MedDuchnowski P, Śmigielski W, Kołsut P.
europepmc +3 more sources
Cardiogenic shock - novelty and emerging therapeutic concepts [PDF]
Българска кардиология, 2022 The cardiogenic shock is a state of low cardiac output, primarily due to cardiac dysfunction, which leads to severe organ hypoperfusion with tissue hypoxia and increased lactate levels. It presents a severe complication with a prevalence of around 15% of
I. Petrov, Z. Stankov, S. Vasilev
doaj +3 more sources
Frontiers in Cardiovascular Medicine, 2022 Left ventricular assist device (LVAD) therapy has been instrumental in saving lives of patients with end-stage heart failure (HF). Recent generation devices have short-to-mid-term survival rates close to heart transplantation. Unfortunately, up to 1 in 4
Mahmoud Abdelshafy +15 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2023 The role of the beta-adrenergic signaling pathway in heart failure (HF) is pivotal. Early blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line medication for patients with HF and reduced ejection fraction (HFrEF ...
Guillaume Schurtz +19 more
doaj +1 more source
Advanced heart failure: state of the art and future directions [PDF]
Reviews in Cardiovascular Medicine, 2022 Advanced heart failure is a clinical challenge that requires a pathophysiological-based approach. As the field has been the subject of multiple reviews, the objective of this paper is not to duplicate these publications but rather to offer practical ...
Daniele Masarone +3 more
doaj +1 more source
McGill Journal of Medicine, 2022 Shock is a life-threatening pathophysiologic state referring to inadequate organ perfusion, which can progress to end-organ dysfunction and eventually, multiple organ failure and death. The diagnosis of shock is clinical, necessitating good understanding
Janet Chan
doaj +1 more source